SCHEMBL1197965

SCHEMBL1197965

O=C(O)c1cnn(Cc2nc(-c3cc(OCc4ccc(F)cc4F)cc(C(F)(F)F)c3)cs2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALKBH1 Q13686 8/20 0.49
PPARD Q03181 1/20 0.39
KDM5A P29375 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
KDM5B Q9UGL1 1/20 0.38
PTGER1 P34995 2/20 0.37
ALDH1A1 P00352 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MAOB P27338 1/20 0.36
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
CASP3 P42574 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
PPARA Q07869 1/20 0.35
KLKB1 P03952 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1199018 0.90 ALDH1A1 (0.41) ALKBH1PPARDPTGER1ALDH1A1L3MBTL1
SCHEMBL2868652 0.90 ALKBH1 (0.45) ALKBH1PPARDKDM5AKDM4CKDM5B
SCHEMBL12876136 0.89 ALKBH1 (0.50) ALKBH1PPARDKDM5AKDM4CKDM5B
SCHEMBL2859042 0.88 ALKBH1 (0.49) ALKBH1PPARDKDM5AKDM5BALDH1A1
SCHEMBL2861439 0.87 ALKBH1 (0.51) ALKBH1PPARDKDM5AKDM4CKDM5B
SCHEMBL2860292 0.86 ALDH1A1 (0.42) ALKBH1PPARDALDH1A1L3MBTL1KDM4E
SCHEMBL12876610 0.84 PPARD (0.39) PPARDKDM4CPTGER1ALDH1A1L3MBTL1
SCHEMBL1198589 0.83 MMP13 (0.40) PPARDKDM4CALDH1A1L3MBTL1KDM4E
SCHEMBL2861391 0.83 KDM4E (0.40) PPARDPTGER1ALDH1A1L3MBTL1KDM4E
SCHEMBL2858894 0.83 PPARD (0.39) PPARDPTGER1ALDH1A1L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A ALKBH1 1916/4885PPARD 288/4885KDM5A 1057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.